Purpose: To evaluate evolution and elucidate clinical phenotypes related to prognosis of patients with mesial temporal lobe epilepsy related to hippocampal sclerosis (MTLE-HS) treated exclusively with antiepileptic drugs (AED). Methods: Forty-seven out of 68 MTLE-HS patients treated between January 2005 and June 2010 were retrospectively studied for demographic, clinical and outcome data. The population was divided into drug-responder and drug-resistant patients; the latter was divided, according to the duration of the seizure-free periods along their evolution, into patients with at least one seizure-free period longer than one year and those with shorter periods. Variables were compared between drug-responders vs drugresistants and drug-resistants with long seizure-free periods vs drug-resistants without it. Results: There were 7 (15%) drug-responders, 39 (83%) drug-resistants and 1 patient (2%) with an undetermined response. Eighteen (46%) drug-resistant individuals had seizure-free periods longer than one year, with mean duration of 46 months (3.8 years). Since no factor was statistically associated with long seizure-free period within drug-resistants, we can clinically distinguish two phenotypes: women with left HS and late onset of seizures, with poor prognosis, and men with right HS and earlier appearance of seizures, attaining a better outcome. Twenty out of 47 (42.5%) patients followed an intermittent pattern of epilepsy. Conclusions: Non-surgical MTLE-HS drug-resistant patients can achieve long seizure-free periods with AED, but relapses are common. Female gender, left or bilateral lesion and later onset of seizures seem to be bad prognosis factors within MTLE-HS drug-resistant patients.
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on prognosis in MTLE-HS patients treated exclusively with antiepileptic drugs (AED). Furthermore, non-surgical MTLE-HS patients are frequently considered as a homogeneous array with bad prognosis, which can mislead us when we are dealing with an individual patient. Therefore, the aim of the present study is to describe different clinical phenotypes of non-surgical MTLE-HS patients that allow us to forecast more accurately their future evolution in terms of seizures.
Methods

Clinical assessment
We reviewed 68 patients diagnosed of MTLE-HS in the Epilepsy Unit of the Clinica Universidad de Navarra (Pamplona, Spain) from January 2005 to June 2010. Diagnosis was established according to the League Against Epilepsy criteria, 17 through a detailed neurologic evaluation based on clinical features and MRI evidence of HS. Non-surgical patients were selected for further studies. For each one, we collected the variables of interest by reviewing medical records. Data included demography (age and gender), risk factors for epilepsy (family history, background of perinatal distress and febrile convulsions), clinical features (age at first seizure, presence of secondarily generalized seizures, epileptic discharges in EEG and side of HS in MRI) and AED regimen with its response.
To determine the AED response, we used the recently published definition of drug-resistant epilepsy. It was defined as failure of adequate trials of two tolerated, appropriately chosen and used AEDs schedules (whether as monotherapy or in combination) to achieve sustained seizure freedom. Seizure freedom was defined as a period without seizures for a minimum of three times the longest preintervention interseizure interval (determined from seizures occurring within the past 12 months) or 12 months, whichever is longer. 18 In addition, seizure patterns of relapse and remission were determined, according with a recently published paper. 19 Patients were categorized into two groups: continuous pattern, with no period of remission, and intermittent pattern, in which patients had at least one period of remission. Remission was defined as the presence of a period of at least two years without seizures.
Statistical analysis
Distribution of the variables was studied using the Kolmogorov Smirnoff test method. In the first step we compared baseline demographic and clinical characteristics between drug-responder and drug-resistant patients. In a second step, we compared the same variables between drug-resistant patients with at least one seizure-free period longer than one year and drug-resistant patients without it. All variables followed a parametric distribution and were studied by independent Sample t-test (two variables) in ordinal variables and Chi Square in categorical variables. Afterwards, all variables were studied by binary logistic regression and adjusted by age of onset and years of epilepsy evolution to determine the risk of a poor response to AED and a lack of periods longer than one year without seizures. Statistical analysis were performed using the Statistical Package for the Social Sciences (SPSS) version 16.0; p values of <0.05 were regarded as significant.
Results
Baseline features
We collected data of 47 non-surgical MTLE-HS patients (15 males, 32 females). Age at the time of evaluation ranged between 22 and 71 years (mean AE SD: 44 AE 12.4). Epilepsy onset age was known in 39 patients and the mean was 19.3 AE 15.2 years (range: 1-52); the mean disease evolution reached 24.2 AE 13.7 years (range: 1-46). The background revealed familiar history of epilepsy in 8 (17%), perinatal injury in 8 (17%) and febrile convulsions in 12 (25.5%) patients. Forty-two (89%) subjects had secondarily generalized tonicclonic seizures and EEG showed interictal epileptiform discharges in 26 (55%) patients. HS was unilateral in 43 patients (20 in right lobe and 23 in left lobe) and 4 patients had bilateral damage.
Globally, patients were treated with 18 different AED, with a mean of 5 each one (range 1-13). Most used drugs were carbamazepine (CBZ) in 32, lamotrigine (LTG) in 28, valproic acid (VPA) in 28 and levetiracetam (LEV) in 26 individuals. Taking into account the definitions described above, 39 patients were drugresistant (83%), 7 drug-responder (15%) and 1 had an undetermined response (2%). Baseline features data are summarized in Table 1 .
We found 25/47 subjects (53%) with at least one seizure-free period longer than one year: 7 drug-responder and 18 drugresistant. Mean duration of these intervals was 59 months (almost 5 years). At the time we finished the study, periods reached 93 months (more than 7 years) for drug-responder patients and 46 months (almost 4 years) for drug-resistant ones. Regarding to AED schedule, six drug-responder patients were on monotherapy, with CBZ (2), VPA (1), LTG (1), phenytoin (PHT [1] ) and oxcarbazepine (OXC [1] ); the only patient on bitherapy was on VPA plus topiramate (TPM). Concerning to the 18 drug-resistant patients, 8 (44%) were on monotherapy (CBZ, OXC, VPA or LEV), 6 (33%) on bitherapy (CBZ was the most used AED) and 4 (23%) on three AED.
At the end of the follow-up, 31 patients (66%) continued having seizures, whereas 16 (34%) had become seizure-free. Four patients achieved this condition with the first AED tried (VPA, LTG, PHT and OXC), 3 patients on bitherapy and 9 patients tried more than 2 AEDs before attaining seizure freedom.
Clinical phenotypes based on response to AED
Proportion of females was higher in drug-resistant patients group than in drug-responder one (74% vs 29%; p = 0.029). Side of HS was different in drug-responders than in drug-resistant patients, with higher frequency of subjects with left or bilateral HS in patients with poor response to AED (64% vs 14%; p = 0.033). However, none of the other clinical features showed statistically significant differences between drug-responders and drug-resistant individuals. Logistic regression analysis was not performed due to the unbalanced number of patients in each group, which could lead to mistaken association. Within drug-resistant patients group, we did not find statistically significant differences comparing drug-resistant subjects with a seizure-free period longer than one year with those who did not achieve that seizure freedom gap. Moreover, logistic regression did neither show any clinical factor significantly associated with higher resistance. Nonetheless, some features showed a tendency: patients without seizure freedom periods were more frequently women (81% vs 67%; p = 0.46), they had their first seizure later (22.4 years vs 15.5; p = 0.22) and their MRI showed more frequently left HS (71% vs 56%; p = 0.34). These results are detailed in Table 2 .
Patterns of evolution
Following the patterns of evolution in people with refractory epilepsy described by Neligan et al., 19 we found 27 patients (57.5%) developing a continuous pattern, whereas 20 (42.5%) had an intermittent pattern with at least one period of two years without seizures.
Discussion
MTLE-HS is a usually refractory epilepsy 6 and surgical treatment, mainly amygdalohippocampectomy, should be kept on mind of neurologists when managing this disease. 15 Nonetheless, several reasons lead some patients to be treated only medically, without any surgery. In this retrospective study, we evaluate the evolution over years in a cohort of patients with MTLE-HS treated exclusively with AED. First of all, we discovered that more than half of patients with MTLE-HS (25 out of 47; 53%) had at least one seizure-free period longer than one year, with a mean period without seizures of nearly 5 years. Globally, at the end of follow-up, 16 patients (34%) were seizure free, 7 drug-responder and 9 initially drug-resistant patients. In a subsequent review of our data performed in 2012, all drug-responder patients kept without seizures and on the same treatment; further, one drug-resistant patient underwent an amygdalohippocampectomy in 2011 and remains without seizures 6 months later. These data are concordant with previous reports, where the rate of complete remission ranged from 5% to 42%. 2, 3, 6, [20] [21] [22] Focusing on the 39 drug-resistant patients who were deemed not to be suitable for epilepsy surgery, 18 (46%) became seizure free for at least 1 year; 13 (33%) attained any remission period (2 years without seizures) and 9 (23%) were seizure free at the end of the study. Mean time of periods without seizures was 46 months (almost 4 years). We wish to highlight the significance of these figures: approximately one half of non-surgical drug-resistant patients with MTLE-HS could reach a seizure-free period of at least one year. From these, one half had relapses after that long period without seizures, but the other half (around 25% of all drugresistant patients) achieved complete control with AED. In our opinion, these findings support the notion that the natural history of MTLE-HS is not straightforward. 4 Intractability, therefore, is preceded in some cases by quiescent periods along some years. This phenomenon points to an underlying progressive damage in the whole brain, not only in mesial structures. 23 With AED treatment we are only facing the evident outcome of the disease, namely seizures, but not the epileptogenic events involving a set of cellular, molecular, immunological and genetic changes that shift a normal brain tissue to an epileptic one. Previous studies have pointed to early history of head trauma, female gender, mental retardation 2 and higher initial seizure frequency 13 as bad prognostic features related to poorer control of seizures. We also encountered females developed a more refractory epilepsy. The prognostic role of an early age of seizure onset is contradictory; some studies state that is a good prognosis factor, 21 while others establish the opposite. 2, 7, 22 Our results do not show any difference in that regard. Concerning the side of HS, there is no significant interaction between the side of the lesion and resistance in adults. 2, 22 However, Lindsay et al. described that, in pediatric population, patients with left sided lesions had poorer outcome. 24 In our study, performed in adults, none of the drugresponder patients has unilateral left HS, whereas most of the drug-resistant ones (64%) have a damaged left temporal lobe (unilateral or associated with right HS). Then, since we do not find statistical association, probably due to small number of patients in the drug-responders group, it seems to be a trend to refractoriness in MTLE-HS patients with left damage. Concerning to clinical prognosis factor to predict seizure-free period longer than one year within drug-resistant patients, we have not found any with One explanation for the minimal difference could be that our patients have exclusively HS, without any other lesion, but in their study is not specified if patients have an additional damage, which probably would have impaired the prognosis. Our study has two main limitations: (a) it is a retrospective one; (b) number of patients is too small to draw any definitive conclusion, especially in the drug-responder patients group. On the one hand, the retrospective view of data has the disadvantage that some prognosis factors, which would be interesting to evaluate, were not reported regularly in medical records. One example could be neuropsychological data, which could reflect the functional damage of the hippocampus. On the other hand, the small number of patients makes the validity of statistical data questionable, and the lack of significance of items explored is likely closely related with this limitation. This lack of patients has led us to establish one-year without seizure as the cut-off for the patients to be included in one or another group. In future studies with more patients, one possibility is to set up different cut-offs and to seek different clinical features for each one. Nevertheless, these results can help to point at tendencies that should be tested with larger cohorts of patients, even in multicentre studies including Epilepsy Centres.
In short, approximately one half of non-surgical drug-resistant patients with MTLE-HS could achieve long seizure-free periods only with AED. Female gender and left or bilateral lesion seem to be helpful to forecast the response of one individual patient. Within drug-resistant patients, we have not find any statistically significant factor to predict seizure-free period longer than one year, but female gender, damage in the left hippocampus and later onset of seizures are more frequent in patients without seizure freedom period. Though we are dealing with a resistant sort of epilepsy, different combinations of AED could elicit long periods of seizure freedom with remission periods and an intermittent seizure pattern. Nevertheless, 50% of these patients had relapses and become intractable along the evolution of disease which prompts to a dynamic underlying epileptogenic process over their whole life.
